VIPDOMET 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack

Ülke: Avustralya

Dil: İngilizce

Kaynak: Department of Health (Therapeutic Goods Administration)

Aktif bileşen:

metformin hydrochloride, Quantity: 500 mg; alogliptin benzoate, Quantity: 17 mg (Equivalent: alogliptin, Qty 12.5 mg)

Mevcut itibaren:

Takeda Pharmaceuticals Australia Pty Ltd

INN (International Adı):

Alogliptin benzoate,Metformin hydrochloride

Farmasötik formu:

Tablet, film coated

Kompozisyon:

Excipient Ingredients: microcrystalline cellulose; mannitol; magnesium stearate; titanium dioxide; hypromellose; crospovidone; povidone; purified talc; iron oxide yellow

Uygulama yolu:

Oral

Paketteki üniteler:

196, 20, 120, 14, 28, 112, 60, 56, 200, 98, 180, 10

Reçete türü:

(S4) Prescription Only Medicine

Terapötik endikasyonlar:

VIPDOMET is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,VIPDOMET can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Ürün özeti:

Visual Identification: Pale yellow, oblong, biconvex, film-coated tablet with 12.5/500 debossed on one side and 322M debossed on the other side; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

2013-10-22